5 Clinical Trials to Watch at ASRS 2024

Credit: Max van den Oetelaar/Unsplash

Marking the premier gathering spot for retina science and innovation, the American Society of Retina Specialists (ASRS) 42nd Annual Meeting will convene in Stockholm, Sweden from July 17 to 20, 2024. Landmark trial data will be presented and best-in-class agents will be described and debated across the 4-day meeting.

The HCPLive Ophthalmology editorial team is attending ASRS to gain firsthand insights into the latest advancements and innovations in retinal disease treatment.

Here are 5 top trials expected to be presented at ASRS 2024.

“Four-Year Outcomes of Faricimab in DME: First-Time Safety and Efficacy Results From the RHONE-X Long-Term Extension Trial”

In Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy, Arshad Khanani, MD, director of clinical research at Sierra Eye Associates, will present a late-breaking abstract on first-time safety and efficacy results from the RHONE-X long-term extension study, showing 4-year outcomes of faricimab in the treatment of diabetic macular edema (DME).

The multi-center long-term extension study was designed to evaluate the long-term safety and tolerability of intravitreal faricimab administered at a personalized treatment interval to participants who enrolled in and completed one of the two Phase III studies, YOSEMITE and RHINE.

“Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker For the Treatment of Diabetic Macular Edema (DME)”

In Diabetic Retinopathy Symposium 1, Victor Gonzalez, MD, Valley Retina Institute, will present late-breaking abstract data on the Phase 2a study of CU06-1004, a novel oral endothelial dysfunction blocker, for the treatment of DME.

The study sought to assess the efficacy and safety of orally administered CU06-1004 to improve central subfield thickness (CST) and best-corrected visual acuity (BCVA) and to determine the optimal doses for patients with DME.

“Protective Effects of ANX007 on Central Macular Ellipsoid Zone (EZ) and Retinal Pigment Epithelium (RPE) and Association with Visual Acuity in the Phase 2 ARCHER GA Study”

In Imaging Symposium 1, Glenn J. Jaffe, MD, Duke University Medical Center, will present late-breaking Phase 2 data from the ARCHER study evaluating ANX007 for the treatment of geographic atrophy (GA).

These data will showcase the protective effect of ANX007 on the central macular ellipsoid zone and retinal pigment epithelium, and the association with the preservation of visual function and structure in eyes with GA.

“Interim Safety and Efficacy Results From the Phase 1 HELIOS Trial of Sustained-release Axitinib Implant (OTX-TKI) for NPDR”

In Diabetic Retinopathy Symposium 2, Dilsher S. Dhoot, MD, California Retina Consultants, will present interim safety and efficacy results from the Phase 1 HELIOS trial of sustained-release axitinib implant (OTX-TKI) for non-proliferative diabetic retinopathy (NPDR).

HELIOS is a multi-center, double-masked, randomized, parallel-group study designed to evaluate the safety, tolerability, and efficacy of OTX-TKI compared to a sham control in patients with moderately severe to severe NPDR without center-involved DME.

“Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase 2 Study (NEPTUNE)”

In Inflammatory & Infectious Disease Symposium, Robert Wang, MD, Texas Retina Associates, will present late-breaking 24-week results on the safety and efficacy of brepocitinib for active non-infectious uveitis (NIU) in the Phase 2 NEPTUNE study.

NEPTUNE enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily. The study's primary efficacy endpoint was the rate of treatment failure rate at Week 24 of the 52-week study.

For more on our ASRS coverage, visit our conference page here.